Drug Pricing
Drug Pricing
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
Commentary
Don’t Overreact to Rising Health Spending
U.S. healthcare spending has reached a new high, according to the latest federal data. The Centers for Medicare and Medicaid Services estimate national health expenditures reached $3.8 trillion in 2019, an increase of 4.6 percent over the previous year. That’s just under 18 percent of the national economy. It’s more ...
Commentary
Biden’s health care plans – this is what Americans can expect from Democrats
Last week, President Joe Biden signed executive orders that will re-open ObamaCare’s insurance exchanges from Feb. 15 through May 15 and direct federal agencies to re-examine some of the health care rules enacted by the Trump administration. There’s a limit to what Biden can accomplish by executive action. But with narrow control of Congress, there’s still plenty ...
Blog
It’s the Payment System
Effectively addressing the drug affordability problem requires an understanding of its causes. Toward this end, the rhetoric of Matt Eyles, the president and chief executive of America’s Health Insurance Plans (AHIP), is unhelpful. According to Eyles, “Americans are being hurt by out-of-control drug prices, which are set and fully controlled ...
Drug Pricing
NEW BRIEF: Tearing Down Drug ‘Rebate Walls’ Would Save Patients, Improve Health Care Outcomes
Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click ...
Blog
PRI’s 2020 Free-Market Election Analysis
For hard-working Californians who are busy with their everyday lives, it can be hard to sort through the various measures we’ll be voting on this November. To help you get educated on the issues, below are links to PRI’s free-market analysis on the November ballot. We hope you will find ...
Drug Importation
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Commentary
Import German drug prices to the United States? Nein, danke
President Trump recently issued a blitz of executive orders in an attempt to fulfill his promise to reduce drug prices. One of those orders would put in place a “cure” far worse than the disease. The order in question establishes foreign reference pricing, whereby the federal government ties its reimbursement rates for ...
Drug Pricing
Wayne Winegarden Featured in Newsweek Drug Pricing Story
Title: Big Pharma Backs Joe Biden, But People Don’t Think He’ll Fix Drug Pricing By Darragh Roche Former Vice President Joe Biden is winning the race for donations from Big Pharma but experts and industry stakeholders doubt his plans will successfully lower drug prices or address underlying issues in the ...
Drug Pricing
NEW BRIEF: Mandating that Drug Rebates Benefit Consumers Will Help Patients with High Out-of-Pocket Drug Costs
A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, ...
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
Don’t Overreact to Rising Health Spending
U.S. healthcare spending has reached a new high, according to the latest federal data. The Centers for Medicare and Medicaid Services estimate national health expenditures reached $3.8 trillion in 2019, an increase of 4.6 percent over the previous year. That’s just under 18 percent of the national economy. It’s more ...
Biden’s health care plans – this is what Americans can expect from Democrats
Last week, President Joe Biden signed executive orders that will re-open ObamaCare’s insurance exchanges from Feb. 15 through May 15 and direct federal agencies to re-examine some of the health care rules enacted by the Trump administration. There’s a limit to what Biden can accomplish by executive action. But with narrow control of Congress, there’s still plenty ...
It’s the Payment System
Effectively addressing the drug affordability problem requires an understanding of its causes. Toward this end, the rhetoric of Matt Eyles, the president and chief executive of America’s Health Insurance Plans (AHIP), is unhelpful. According to Eyles, “Americans are being hurt by out-of-control drug prices, which are set and fully controlled ...
NEW BRIEF: Tearing Down Drug ‘Rebate Walls’ Would Save Patients, Improve Health Care Outcomes
Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click ...
PRI’s 2020 Free-Market Election Analysis
For hard-working Californians who are busy with their everyday lives, it can be hard to sort through the various measures we’ll be voting on this November. To help you get educated on the issues, below are links to PRI’s free-market analysis on the November ballot. We hope you will find ...
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Import German drug prices to the United States? Nein, danke
President Trump recently issued a blitz of executive orders in an attempt to fulfill his promise to reduce drug prices. One of those orders would put in place a “cure” far worse than the disease. The order in question establishes foreign reference pricing, whereby the federal government ties its reimbursement rates for ...
Wayne Winegarden Featured in Newsweek Drug Pricing Story
Title: Big Pharma Backs Joe Biden, But People Don’t Think He’ll Fix Drug Pricing By Darragh Roche Former Vice President Joe Biden is winning the race for donations from Big Pharma but experts and industry stakeholders doubt his plans will successfully lower drug prices or address underlying issues in the ...
NEW BRIEF: Mandating that Drug Rebates Benefit Consumers Will Help Patients with High Out-of-Pocket Drug Costs
A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, ...
